|
 The companies will develop and commercialize T-cell receptor
therapies (TCR-Ts), using Immatics' proprietary technology, with the
German company primarily responsible for development and validation
of the treatments and GSK looking into worldwide development.
T-cell receptors (TCRs) are a class of compounds that make it easier
for the body's immune cells to identify and destroy cancer cells,
while TCR-Ts detect targets both inside and outside the cancer
cells.
The deal underscores GSK's development work on cell and gene
therapies against solid tumours, while the wider industry's focus
has been mainly on blood cancer.
[to top of second column] |
Immatics will get an upfront payment of $50 million for two initial
programs under the agreement and is eligible to get more than $550
million in further payments.
In October 2018 the British drugmaker entered a five-year
collaboration with Lyell Immunopharma, another private biotechnology
company that focuses on developing engineered T-cells targeting
common solid tumours.
(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in
Frankfurt; Editing by Shounak Dasgupta)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
